Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC1 | P07992 | 3/20 | 0.37 |
| ▸ | ERCC4 | Q92889 | 3/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 6/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.34 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.31 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.31 |
| ▸ | THRA | P10827 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | ARG1 | P05089 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL175682 | 0.72 | GAA (0.40) | ADRB2ADRB1THRB | |
| SCHEMBL4483486 | 0.70 | ADRB3 (0.50) | ERCC1ERCC4ADRB2ADRB1ADRB3 | |
| SCHEMBL3288652 | 0.65 | ERCC1 (0.57) | ERCC1ERCC4ADRB2ADRB1ADRB3 | |
| SCHEMBL108628 | 0.64 | ERCC1 (0.79) | ERCC1ERCC4 | |
| SCHEMBL175681 | 0.64 | PPARD (0.50) | THRB | |
| SCHEMBL175736 | 0.62 | YWHAG (0.53) | ERCC1ERCC4ADRB2 | |
| SCHEMBL109055 | 0.62 | ADRB3 (0.65) | ADRB2ADRB1ADRB3 | |
| SCHEMBL175651 | 0.61 | APP (0.57) | ADRB2 | |
| SCHEMBL17779423 | 0.60 | HPGD (0.40) | ADRB2ADRB1ADRB3 | |
| SCHEMBL17498275 | 0.59 | CA1 (0.52) | THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090197965-A1 | Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; Alzheimer's disease; diabetes; A beta amyloidosis | SNOW ALAN D | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197965-A1 | Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; Alzheimer's disease; diabetes; A beta amyloidosis | IAPP, APP, SNCA | ERCC1 4117/4885ERCC4 4337/4885ADRB2 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.